The price of Odivo, also known as navumab, ranges from $4,000 to $10,000, depending on the specifications. Navumab is a monoclonal antibody to PD-1 that is commonly used in the clinic to help enhance the anticancer effect of T-cells by blocking PD-1 and its ligand, PDL-1/2, so as to achieve the effect of controlling the disease. Navumab is currently available in 100mg/10ml and 40mg/4ml specifications, the price of which is around RMB 4,000 and RMB 10,000 respectively, and the price may vary from region to region and from hospital to hospital. The common adverse reactions of navumab include immune-mediated pneumonia, colitis, hepatitis, nephritis, etc. It is used with caution in pregnancy, breastfeeding, children and the elderly, and is contraindicated in those who are allergic to the product. Navucizumab should be used under the guidance of a doctor, do not blindly use the drug, in order to avoid delays in the condition.